Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Factors Affecting Protein-Drug Binding: Drug Interactions

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025

Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020

Same author

Pharmacokinetics of tenofovir during pregnancy and postpartum.

HIV medicine·2015

Same author

Helicase-primase as a target of new therapies for herpes simplex virus infections.

Clinical pharmacology and therapeutics·2015

Same author

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

Clinical pharmacology and therapeutics·2014

Same author

Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo.

Clinical pharmacology and therapeutics·2010

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Antiretroviral drug interactions.

E P Acosta¹, C V Fletcher

¹Department of Pharmacy Practice, College of Pharmacy, The University of Minnesota, 7-115 Health Sciences Unit F. 308 Harvard St. S.E., Minneapolis, MN 55455, USA.

International Journal of Antimicrobial Agents

|April 1, 1995

Summary

Individuals with acquired immunodeficiency syndrome (AIDS) often take multiple medications, leading to complex drug interactions. Understanding these interactions is crucial for effective lifelong treatment strategies in human immunodeficiency virus (HIV) management.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

Pharmacology
Infectious Diseases
Clinical Pharmacy

Background:

Patients with acquired immunodeficiency syndrome (AIDS) are prescribed an average of 5.6 medications, potentially increasing to 9.
The increasing complexity of antiretroviral agents and drugs for opportunistic infections in human immunodeficiency virus (HIV) disease necessitates a thorough understanding of polypharmacy.

Purpose of the Study:

To address antiretroviral drug interactions from pharmacokinetic and pharmacodynamic perspectives.
To provide an optimal pharmacologic strategy for managing drug interactions in lifelong HIV treatment.

Main Methods:

Review of clinical pharmacology of antiretroviral agents.
Discussion of selected drug interactions.

Main Results:

Antiretroviral drug interactions present significant challenges in managing HIV disease.
Understanding pharmacokinetic and pharmacodynamic interactions is essential for safe and effective combination therapy.

Conclusions:

Lifelong antiretroviral therapy and opportunistic infection management require careful consideration of drug-drug interactions.
A comprehensive approach to drug interactions is vital for optimizing pharmacologic strategies in HIV care.